Comment from UCB, Inc.

Summary: UCB, Inc., a global biopharmaceutical company, supports the draft guidance and provides specific recommendations to improve clarity and scope. They suggest expanding the scope to include other RNA-based therapies, refining language on nonclinical data and biomarkers, and clarifying requirements for patient diagnosis and master protocols.